{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.9","upperLimit":"47.3","value":"34"},{"groupId":"OG001","lowerLimit":"23.5","upperLimit":"47.6","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"description":"CBR was determined by the investigator according to the 2016 IMWG response criteria. CBR was calculated as the percentage of participants with a confirmed MR or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 2.5 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 39 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG000","title":"Main Study: GSK2857916 2.5 mg/kg (Frozen Liquid)"},{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 3.4 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 32 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG001","title":"Main Study: GSK2857916 3.4 mg/kg (Frozen Liquid)"}],"paramType":"NUMBER","populationDescription":"Efficacy Population. Data is not presented for 'GSK2857916 3.4 mg/kg (Lyophilized)' arm as it is not included in Efficacy Population.","reportingStatus":"POSTED","timeFrame":"Up to 186 weeks","title":"Clinical Benefit Rate by Investigator Assessment (Efficacy Population)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}